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Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates surface expression of the low density lipoprotein (LDL) receptor 
(LDL-R), increasing circulating LDL cholesterol (LDL-C). Statins increase LDL-R and PCSK9 levels. AMG 145, a fully human monoclonal antibody 
against PCSK9, has been demonstrated to lower LDL-C in healthy volunteers; its use may further reduce LDL-C in subjects taking a statin. This study 
assessed the safety and tolerability of repeated doses of AMG 145 and its effect on plasma LDL-C in subjects on stable doses of a statin.
Methods: In cohorts 1-5 (dose escalation), subjects with LDL-C 70-200 mg/dL on stable daily rosuvastatin <40 mg, atorvastatin <80 mg or 
simvastatin 20-80 mg for ≥1 month were randomized 3:1 to receive subcutaneous (SC) AMG 145 or placebo. Each higher-dose cohort was initiated 
sequentially after the tolerability of the lower dose was established. Dosing ranged from once-weekly (6 doses) to once every 4 weeks (2 doses). In 
a 6th cohort, subjects were on either rosuvastatin 40 mg or atorvastatin 80 mg; they received the same regimen as cohort 3: AMG 145 or placebo 
once every 2 weeks (3 doses).
Results: Subjects (N = 51) were randomized to receive AMG 145 (N = 39) or placebo (N =1 2); 26 subjects (51%) were male; mean (SD) age 
was 58 (7) years. No deaths or serious adverse events (AEs) were reported and no subjects discontinued the study due to an AE. No neutralizing 
antibodies to AMG 145 were detected. Subjects on low to moderate doses of statins had mean LDL-C reductions of up to 75% vs placebo at week 
6 after 3 biweekly SC doses of AMG 145, and 66% at week 8 after 2 SC doses given every 4 weeks. The magnitude and duration of effect were dose-
dependent. Plasma PCSK9 was undetectable at higher doses. Similarly, at week 6 after 3 biweekly doses, subjects on high-dose statins (cohort 6) 
had a mean reduction in LDL-C of 63% vs placebo.
Conclusions: Repeated SC doses of AMG 145 over 6-8 weeks were well tolerated and decreased circulating LDL-C up to 75% vs placebo, 
depending on dosing regimen, in subjects on either low/moderate- or high-dose statins. The LDL-C-lowering effect of AMG 145 was similar between 
the high dose statin and low-to-moderate statin dose groups.
